Ad is loading...
EPRX
Price
$3.13
Change
+$0.23 (+7.93%)
Updated
Nov 15 closing price
134 days until earnings call
NKGN
Price
$0.26
Change
-$0.02 (-7.14%)
Updated
Nov 15 closing price
Ad is loading...

EPRX vs NKGN

Header iconEPRX vs NKGN Comparison
Open Charts EPRX vs NKGNBanner chart's image
Eupraxia Pharmaceuticals
Price$3.13
Change+$0.23 (+7.93%)
Volume$15.58K
CapitalizationN/A
NKGen Biotech
Price$0.26
Change-$0.02 (-7.14%)
Volume$446.23K
CapitalizationN/A
EPRX vs NKGN Comparison Chart
Loading...
NKGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
EPRX vs. NKGN commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EPRX is a Sell and NKGN is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (EPRX: $3.13 vs. NKGN: $0.26)
Brand notoriety: EPRX and NKGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EPRX: 137% vs. NKGN: 30%
Market capitalization -- EPRX: $110.95M vs. NKGN: $9.33M
EPRX [@Biotechnology] is valued at $110.95M. NKGN’s [@Biotechnology] market capitalization is $9.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EPRX’s FA Score shows that 0 FA rating(s) are green whileNKGN’s FA Score has 0 green FA rating(s).

  • EPRX’s FA Score: 0 green, 5 red.
  • NKGN’s FA Score: 0 green, 5 red.
According to our system of comparison, EPRX is a better buy in the long-term than NKGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NKGN’s TA Score shows that 3 TA indicator(s) are bullish.

  • NKGN’s TA Score: 3 bullish, 6 bearish.

Price Growth

EPRX (@Biotechnology) experienced а -2.61% price change this week, while NKGN (@Biotechnology) price change was -1.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

EPRX is expected to report earnings on Apr 01, 2025.

NKGN is expected to report earnings on Mar 31, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EPRX($111M) has a higher market cap than NKGN($9.33M). EPRX YTD gains are higher at: -24.764 vs. NKGN (-90.404). EPRX has higher annual earnings (EBITDA): -26.35M vs. NKGN (-77M). EPRX has more cash in the bank: 23.3M vs. NKGN (34K). EPRX has less debt than NKGN: EPRX (4.66M) vs NKGN (22.2M). EPRX (0) and NKGN (0) have equivalent revenues.
EPRXNKGNEPRX / NKGN
Capitalization111M9.33M1,189%
EBITDA-26.35M-77M34%
Gain YTD-24.764-90.40427%
P/E RatioN/AN/A-
Revenue00-
Total Cash23.3M34K68,529%
Total Debt4.66M22.2M21%
TECHNICAL ANALYSIS
Technical Analysis
NKGN
RSI
ODDS (%)
Bearish Trend 3 days ago
14%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
43%
Momentum
ODDS (%)
Bearish Trend 3 days ago
38%
MACD
ODDS (%)
Bullish Trend 3 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
57%
Advances
ODDS (%)
Bullish Trend 11 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
35%
Aroon
ODDS (%)
Bearish Trend 3 days ago
72%
View a ticker or compare two or three
Ad is loading...
NKGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRIIX17.04-0.01
-0.06%
Baron Real Estate Income Institutional
FGDAX24.67-0.11
-0.44%
Fidelity Advisor Gold A
RMATX10.81-0.05
-0.46%
Russell Inv Multi-Asset Growth Strat M
RYIAX118.51-2.55
-2.11%
Rydex Internet H
FATIX140.54-3.36
-2.33%
Fidelity Advisor Technology I

EPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EPRX has been loosely correlated with CRBU. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EPRX jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPRX
1D Price
Change %
EPRX100%
+7.96%
CRBU - EPRX
40%
Loosely correlated
-4.78%
NRXP - EPRX
27%
Poorly correlated
+2.59%
VIR - EPRX
23%
Poorly correlated
-7.29%
LEXX - EPRX
23%
Poorly correlated
-5.19%
ACAD - EPRX
22%
Poorly correlated
-1.47%
More

NKGN and

Correlation & Price change

A.I.dvisor tells us that NKGN and MTEM have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NKGN and MTEM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKGN
1D Price
Change %
NKGN100%
-4.76%
MTEM - NKGN
33%
Poorly correlated
-23.41%
APM - NKGN
31%
Poorly correlated
-38.00%
PHGE - NKGN
23%
Poorly correlated
-17.33%
EPRX - NKGN
22%
Poorly correlated
+7.96%
HXBM - NKGN
22%
Poorly correlated
N/A
More